Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia 2022 Mar;36(3):877-880
Date
11/22/2021Pubmed ID
34802043DOI
10.1038/s41375-021-01471-3Scopus ID
2-s2.0-85119448679 (requires institutional sign-in at Scopus site) 14 CitationsAuthor List
Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, Cornell RF, Kang Y, Umyarova E, Giri S, Chhabra S, Liedtke M, Callander NS, Hari P, Kumar S, Costa LJMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Benchmarking
Female
Humans
Male
Middle Aged
Multiple Myeloma
Treatment Outcome